Home » Newsletters » BioWorld Science

BioWorld Science

June 30, 2003

View Archived Issues

Phase II findings for onercept in psoriasis and psoriatic arthritis

Peregrine presents antibodies targeting phosphatidylserine

Applied Molecular Evolution to optimize Lilly protein therapeutic candidates

Gilead and Bukwang clevudine licensing agreement terminated

Curis collaboration focusing on Hedgehog signaling pathway

Lorus selects lead antisense compound to target thioredoxin

Inflazyme completes acquisition of GlycoDesign

Y-700 found to inhibit uric acid formation in healthy adult volunteers

SCV-07 stimulates Th1 immune response in TB animal model

Analgesic effects reported for gabapentin in chronic radiculopathy

SMP-114 has good safety profile in healthy volunteers

Durable clinical response found for alefacept plus methotrexate in severe rheumatoid arthritis

Clinical benefits of a human monoclonal antibody against IL-15 in active rheumatoid arthritis

Three series of CCR3 antagonists with utility in asthma therapy claimed by Roche

New GABA-C receptor antagonists and their use as cognition-enhancing agents

Antitumor epothilones identified by Kosan scientists

Pharmacia (Pfizer) team identifies novel pyrazine-based CRF1 antagonists

Apoptosis inducers prepared and tested at the Burnham Institute

Scientists at Fujisawa and Daiso present novel apo B secretion inhibitors

New factor Xa inhibitors and their use covered by Warner-Lambert patent

Idec and Biogen to merge

Enbrel recommended by FDA panel to treat ankylosing spondylitis

Savient chosen as new corporate name for Bio-Technology General

Pilot study of Probuphine initiated for treatment of opiate addiction

MLN-2201 enters phase I testing

CPMP hands down positive opinion for survival claim for MabCampath

European Commission grants marketing authorization for Aldurazyme in Europe

FDA clears IND for dextofisopam for IBS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...